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Abstract
Background: Glutamergic excitotoxicity has been shown to play a deleterious role in the pathophysiology of
spinal cord injury (SCI). The aim of this study was to investigate the neuroprotective effect of dizocilpine maleate,
MK801 (2 mg/Kg, 30 min and 6 hours after injury) in a mice model of SCI. The spinal cord trauma was induced by
the application of vascular clips to the dura via a four-level T5-T8 laminectomy.
Results: Spinal cord injury in mice resulted in severe trauma characterized by edema, neutrophil infiltration and
apoptosis. In this study we clearly demonstrated that administration of MK801 attenuated all inflammatory
parameters. In fact 24 hours after injury, the degree of spinal cord inflammation and tissue injury (evaluated as
histological score), infiltration of neutrophils, NF-B activation, iNOS, cytokines levels (TNF-a and IL-1b),
neurotrophin expression were markedly reduced by MK801 treatment. Moreover, in a separate set of experiments,
we have demonstrated that MK801 treatment significantly improved the recovery of locomotory function.
Conclusions: Blockade of NMDA by MK801 lends support to the potential importance of NMDA antagonists as
therapeutic agents in the treatment of acute spinal cord injury.
1. Background
Spinal cord injury (SCI) is a highly debilitating pathology
that has irreversible impacts and results in functional
lost. Paraplegia remains one of the major complications
after operations. The complex pathophysiology of SCI
may explain the difficulty in finding a suitable therapy.
The traumatic mechanical injury to the spinal cord, that
is incurred following blunt impact and compression, is
called “primary injury”; it directly destroys various ele-
ments of the tissue [1]. Normally, acute injury leads to
chronic injury and this successive phase is called “second-
ary injury”, that lead to further tissue damage and expan-
sion of the lesion for many days to months [2].
An effective treatment limiting the evolution of second-
ary damage is still missing. Historically, administration of
high-dose glucocorticoid steroid acutely after SCI has
been considered the standard of care, but there have
been growing concerns that the modest neurological
improvements seen with high-dose methylprednisolone
treatment in injured patients are not worth the associated
risks. Therefore, there is a critical need to develop new
pharmacologic therapies for treatment of SCI.
Excitotoxic damage due to excess release of neuronal
glutamate is hypothesized to play a deleterious role in the
pathogenesis of SCI. Glutamate is involved in fast excita-
tory transmission and plays important roles in neuronal
function such as plasticity and cognitive processes, as
well as in toxic events [3]. It is stored in synaptic vesicles
and released by calcium (Ca
2+)-dependent exocytosis in
the white matter of the brain [4]. Moreover, glutamate
also activates N-methyl D-aspartate (NMDA) receptors
in oligodendrocytes. Increasing evidences suggest that
these receptors may be a novel therapeutic target for pre-
venting white matter pathology [5,6]. The NMDA recep-
tors are opened or closed in response to the binding of a
chemical messenger. These receptors are most abundant
in the cortex, basal ganglia, in the sensory pathways of
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any medium, provided the original work is properly cited.the nervous system, but has also been identified in a vari-
ety of non-neuronal and peripheral locations [7]. Five
NMDA receptor subunits are expressed in the brain [8]:
the NR1 subunit is necessary for channel function;
instead the NR2 subunits have long C-terminal tails ser-
ving as anchoring points for signal transduction enzymes
[9]. The channel pore is normally blocked by Mg
2+ to
prevent ion flux [10]; during “secondary injury” [4], char-
acterized by an excessive stimulation of glutamate, the
Mg
2+ blockade is removed causing the opening of the
receptor channel and the release of Ca
2+ within myelin
with changes in dendrite structure and disruption of the
processes of oligodendrocytes [11]. In addition, the over-
stimulation of glutamate receptors is toxic either to neu-
ron and glial cells and participates in processes
culminating in programmed cell death [12,13].
Dizocilpine maleate (MK801) is a potent non competi-
tive NMDA receptor antagonist that blocks the excitotoxic
sequel of ischemia in tissue cultures and animal models of
cerebral ischemia, reduces infarct size, and improves neu-
rological outcome [14]. The efficacy of several NMDA
antagonist drugs have been studied in various models of
ischemic spinal cord injury [15], contusive SCI [16,17] or
in ischemic lesions of rat spinal cord [18], but studies
using the acute clip compression model of spinal cord,
that simulates human injury, are limited and related only
to the recovery and neuronal death [19,20].
Thus the purpose of this study was to examine the
potential contributory factors and molecular aspects of
glutamate receptors that may play a role in excitotoxic
cell death during SCI.
In particular, we demonstrated that the administration
of MK801, 30 min and 6 hours after injury, attenuated
the degree of spinal cord injury; nuclear factor-kappa B
(NF-B) activation; pro-inflammatory cytokines and
enzymes; MAPK activation; proliferation of T cells;
and apoptosis. Interestingly, it restored the levels of
neurotrophins.
2. Methods
2.1 Animals
Male adult CD1 mice (25-30 g, Harlan Nossan, Milan,
Italy) were used for all studies. Mice were housed in
individual cages (5 for each group) and maintained
under 12:12 light-dark cycle at 21 ± 1°C and 50 ± 5%
humidity. The animals were acclimated to their environ-
ment for 1 wk and had ad libitum access to tap water
and standard rodent standard diet. All animal experi-
ments complied with regulations in Italy (D.M. 116192),
Europe (O.J. of E.C. L 358/1 12/18/1986) and USA (Ani-
mal Welfare Assurance No A5594-01, Department of
Health and Human Services, USA). All behavioral test-
ing was conducted in compliance with the NHI labora-
tory animal care guidelines and with protocols approved
by the Institutional Animal Care and Use Committee
(Council directive # 87-848, October 19, 1987, Ministère
de l’Agriculture et de la Forêt, Service Vétérinaire de la
S a n t ée td el aP r o t e c t i o nA n i m a l e ,p e r m i s s i o n#9 2 - 2 5 6
to SC). The study was approved by the University of
Messina Review Board for the care of animals.
2.2 SCI
Mice were anesthetized using chloral hydrate (400 mg/
kg body weight). We used the clip compression model
described by Rivlin and Tator [21] and produced SCI by
extradural compression of a section of the spinal cord
exposed via a four-level T5-T8 laminectomy. With the
aneurysm clip applicator oriented in the bilateral direc-
tion, an aneurysm clip with a closing force of 24 g was
applied extradurally at T6-T7 level. The clip was then
rapidly released with the clip applicator, which caused
spinal cord compression. In the injured groups, the cord
was compressed for 1 min. Following surgery, 1.0 cc of
saline was administered subcutaneously in order to
replace the blood volume lost during the surgery. Dur-
ing recovery from anesthesia, the mice were placed on a
heating pad and covered with a warm towel. The mice
were singly housed in a temperature-controlled room at
27°C for a survival period of 24 hours. Food and water
were provided to the mice ad libitum. During experi-
mental period, the animal’sb l a d d e r sw e r em a n u a l l y
voided twice a day until the mice were able to regain
normal bladder function. Sham-injured animals were
only subjected to laminectomy. Spinal cord tissues were
taken at 24 h following trauma. Tissue segments con-
tained the lesion (1 cm on each side of the lesion), in
according to counts of retrogradely labeled neurons at
the origin of distinct descending motor pathways and to
morphometric assessments of normal residual tissue at
the injury epicenter, as previously described by Joshi
and Fehlings [22].
2.3 Experimental Groups
Mice were randomly assigned to the following groups:
SCI+vehicle group (N =2 0 ) :m i c ew e r es u b j e c t e dt o
SCI plus administration of saline (the volume of saline
administered was more or less of 250-300 μl, based on
the weight of each mouse);
SCI +MK801 group (N = 20): As the SCI + vehicle
group but in which MK801 at the dose of 2 mg/kg was
administered i.p. 30 min and 6 hours after surgical
procedures;
Sham+vehicle group (N = 20): mice were subjected to
the surgical procedures as the above groups except that
the aneurysm clip was not applied (only laminectomy) and
they were treated i.p. with saline (the volume of saline
administered was more or less of 250-300 μl, based on the
weight of each mouse);
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vehicle group except that MK801 was administered i.p.
30 min and 6 hours after laminectomy. The use of this
“therapeutic time window” in mice (30 min and 6 h
after SCI) is related to blunt the changes of extracellular
ionic levels after injury (30 min-1 h) and to block the
post-traumatic cascade at several sites (6 h). The dose
of MK801 used here was based on a previous dose-
response study in our laboratory. MK801 (Tocris
Bioscience) were dissolved in physiological saline.
2.4 Grading of motor disturbance
The motor function of mice subjected to compression
trauma was assessed once a day for 20 days after injury.
Recovery from motor disturbance was graded using the
Basso Mouse Scale (BMS) open-field score [23], since
the BMS has been shown to be a valid locomotor rating
scale for mice. The evaluations were made by two blind
observers for all analyzed groups. Briefly, the BMS is a
nine-point scale that provides a gross indication of loco-
motor ability and determines the phases of locomotor
recovery and features of locomotion. The BMS scale
ranges from 0 (indicating complete paralysis) to 9 (indi-
cating normal hind limb function), rating locomotion on
aspects of hind limb function such as weight support,
stepping ability, coordination, and toe clearance. The
BMS score was determined for ten mice in each group.
2.5 Determination of myeloperoxidase (MPO) activity
MPO activity, an indicator of polymorphonuclear leuko-
cyte (PMN) accumulation, was determined in the spinal
cord tissue as previously described [24] at 24 hours after
S C I .A tt h es p e c i f i ct i m ef o llowing SCI, spinal cord tis-
sues were obtained and weighed and each piece of tissue
was homogenized in a solution containing 0.5% hexa-
decyl-trimethyl-ammonium bromide (HTBA) dissolved
in 10 mM potassium phosphate buffer (pH 7) and cen-
trifuged for 30 min at 20,000 × g at 4°C. An aliquot of
the supernatant was then allowed to react with a solu-
tion of 1.6 mM tetra-methyl-benzidine and 0.1 mM
H2O2. The rate of change in absorbance was measured
spectrophotometrically at 650 nm. MPO activity was
defined as the quantity of enzyme degrading 1 μmol of
peroxide min at 37°C and was expressed as units of
MPO/mg of proteins.
2.6 ELISA measurement of TNF-a and IL-1b
The measurement of cytokines levels, 1 cm sample con-
taining the lesion site (or comparable region of sham
operated animals), was rapidly dissected and homoge-
nized in 1 ml PBS containing protease inhibitors (Com-
plete protease inhibitor tablets, Roche). TNF-a and
IL-1b levels were assayed using DuoSet ELISA Develop-
ment System (R&D Systems). All assays were carried
out in duplicate using recommended buffers, diluents
and substrates. Absorbency was determined using a
microplate reader at 450 nm (Thermo Scientific, Multis-
kan FC Microplate Photometer). The intra-assay coeffi-
cient of variations for both assays was less than 10%.
The concentration of the cytokines in the tissue was
mentioned as pg/100 mg wet tissue.
2.7 Light microscopy
At 24 hours after spinal cord injury the animals were
deeply anesthetized and transcardially perfused with
0.1 mol/L phosphate-buffered saline (pH 7.4), followed
by paraformaldehyde in 0.1 mol/L in phosphate-buffered
saline as previously described [25]. Tissue segments con-
taining the lesion (1 cm on each side of the lesion) were
paraffin embedded and cut into 5 μm-thick sections.
Tissue sections (thickness 5 μm) were deparaffinised
with xylene, stained with Haematoxylin/Eosin (H&E), or
with silver impregnation for reticulum and studied using
light microscopy (Dialux 22 Leitz). The segments of
each spinal cord were evaluated by an experienced
histopathology. Damaged neurons were counted and
t h eh i s t o p a t h o l o g yc h a n g e so ft h eg r a ym a t t e rw e r e
scored on a 6-point scale [26]: 0, no lesion observed,
1, gray matter contained 1 to 5 eosinophilic neurons;
2, gray matter contained 5 to 10 eosinophilic neurons;
3, gray matter contained more than 10 eosinophilic neu-
rons; 4, small infarction (less than one third of the gray
matter area); 5, moderate infarction; (one third to one
half of the gray matter area); 6, large infarction (more
than half of the gray matter area). The scores from all
the sections from each spinal cord were averaged to give
a final score for individual mice. The sections were also
submitted to silver impregnation. All the histological
studies were performed in a blinded fashion.
2.8 Immunohistochemical localization of Tumor necrosis
factor (TNF)-a, interleukin (IL)-1, iNOS, COX-2, Nitrotyrosine,
CD30/CD30L, CD4, CD8 alpha/beta, Fas Ligand
At 24 h after SCI, the tissues were fixed in 10% (w/v)
PBS-buffered formaldehyde and 8 μm sections were pre-
pared from paraffin embedded tissues. After deparaffini-
zation, endogenous peroxidase was quenched with 0.3%
(v/v) hydrogen peroxide in 60% (v/v) methanol for
30 min. The sections were permeabilized with 0.1%
(w/v) Triton X-100 in PBS for 20 min. Non-specific
adsorption was minimized by incubating the section in
2% (v/v) normal goat serum in PBS for 20 min. Endo-
genous biotin or avidin binding sites were blocked by
sequential incubation for 15 min with biotin and avidin
(Vector), respectively. Sections were incubated overnight
with anti-TNF-a (Santa Cruz Biotechnology; 1:100 in
PBS, v/v), anti-IL-1b polyclonal antibody (Santa Cruz
Biotechnology, 1:100 in PBS, v/v), anti-COX-2 (Santa
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Transduction Laboratories in PBS, v/v), anti-nitrotyro-
sine rabbit polyclonal antibody (Upstate, 1:500 in PBS,
v/v), anti-CD30 mAb (Santa Cruz Biotechnology 1:100
in PBS, v/v), anti-CD30 ligand mAb (Santa Cruz Bio-
technology 1:100 in PBS, v/v), anti-CD4 (Santa Cruz
Biotechnology 1:100 in PBS, v/v), anti-CD8 alpha (Santa
Cruz Biotechnology 1:100 in PBS, v/v), anti-CD8 beta
(Santa Cruz Biotechnology 1:100 in PBS, v/v), and anti-
Fas-ligand antibody Abcam,1:500 in PBS, v/v). Sections
were washed with PBS, and incubated with secondary
antibody. Specific labeling was detected with a biotin-
conjugated goat anti-rabbit IgG and avidin-biotin perox-
idase complex (Vector). To verify the binding specificity
for nitrotyrosine, TNF-a, FasL, iNOS, Bax, and Bcl-2,
some sections were also incubated with only the primary
antibody (no secondary) or with only the secondary
antibody (no primary). In these situations no positive
staining was found in the sections indicating that the
immunoreactions were positi v ei na l lt h ee x p e r i m e n t s
carried out. Immunocytochemistry photographs (n = 5
photos from each samples collected from all mice in
each experimental group) of the perilesional area were
assessed as previously described [27] by densitometry
using Optilab Graftek software on a Macintosh personal
computer.
2.9 Western blot analysis
Cytosolic and nuclear extracts were prepared as pre-
viously described [28] with slight modifications. Briefly,
spinal cord tissues from each mouse were suspended in
extraction Buffer A containing 0.2 mM phenylmethylsul-
phonyl fluoride (PMSF), 0.15 μMp e p s t a t i nA ,2 0μM
leupeptin, 1 mM sodium orthovanadate, homogenized at
the highest setting for 2 min, and centrifuged at 1,000 ×
g for 10 min at 4°C. Supernatants represented the cyto-
solic fraction. The pellets, containing enriched nuclei,
were re-suspended in Buffer B containing 1% Triton
X-100, 150 mM NaCl, 10 mM TRIS-HCl pH 7.4, 1 mM
ethylene glycol-bis(beta-aminoethyl ether)-N, N, N′,N ′-
tetraacetic acid (EGTA), 1 mM ethylene diamine-tetra-
acetic acid (EDTA), 0,2 mM PMSF, 20 μM leupeptin,
0,2 mM sodium orthovanadate. After centrifugation
30 min at 15,000 × g at 4°C, the supernatants containing
the nuclear protein were stored at -80°C for further ana-
lysis. The levels of IB-a,p h o s p h o - N F - Bp 6 5( s e r i n e
536), n-NOS, p-ERK1/2, p-P38, COX-2, brain-derived
neurotrophic factor (BDNF) and glial cell line-derived
neurotrophic factor (GDNF), were quantified in cytoso-
lic fractions from spinal cord tissue collected 24 h after
SCI, while NF-B p65 levels were quantified in nuclear
fractions. The filters were blocked with 1 × PBS, 5%
(w/v) non fat dried milk (PM) for 40 min at room
temperature and subsequently probed with specific Abs
anti-IB-a (1:2000; Santa Cruz Biotechnology), anti-NF-
B p65 (1:500; Santa Cruz Biotechnology), anti-phos-
pho-P38 (1:1000;Cell Signaling), phospho-NF-Bp 6 5
(serine 536) (Cell Signaling,1:1000), or anti-p-ERK1/2
(1:100 Signal Transduction), anti-nNOS (1:1000 Signal
Transduction), anti-COX-2 (1:500; Cayman), anti-BDNF
(1:500; Santa Cruz Biotechnology), and anti-GDNF
(1:500; Santa Cruz Biotechnology) in 1 × PBS, 5% w/v
non fat dried milk, 0.1% Tween-20 (PMT) at 4°C, over-
night. Membranes were incubated with peroxidase-con-
jugated bovine anti-mouse IgG secondary antibody or
peroxidase-conjugated goat anti-rabbit IgG (1:2000,
Jackson ImmunoResearch, West Grove, PA) for 1 h at
room temperature. To ascertain that blots were loaded
with equal amounts of proteic lysates, they were also
incubated in the presence of the antibody against
a-tubulin or lamin A/C (1:1000 Sigma-Aldrich Corp.).
Signals were detected with enhanced chemiluminescence
detection system reagent according to manufacturer’s
instructions (SuperSignal West Pico Chemiluminescent
Substrate, Pierce). The relative expression of the protein
bands of IkB-a (~37 kDa), phospho-NF-Bp 6 5( s e r i n e
536) (75 kDa), NF-kB p65 (65 kDa), iNOS (~130 kDa),
nNOS (155 kDa), COX-2 (72 kDa), phospho-P38
(42 kDa), BDNF (17 kDa), and GDNF (15 kDa) was
quantified by densitometry with ImageQuant TL soft-
ware (GE Healthcare) and standardized to a-tubulin or
lamin A/C levels. Images of blot signals (8 bit/600 dpi
resolution) were imported to analysis software (Image
Quant TL, v2003). A preparation of commercially avail-
able molecular weight markers (BIO-RAD, Precision
Plus Protein Standard) consisting of proteins of molecu-
lar weight 10 to 250 kDa was used to define molecular
weight positions and as reference concentrations for
each molecular weight.
2.10 Terminal Deoxynucleotidyltransferase-Mediated UTP
End Labeling (TUNEL) Assay
TUNEL assay was conducted by using a TUNEL detec-
tion kit according to the manufacturer’s instruction
(Apotag, HRP kit DBA, Milan, Italy). Sections were
incubated with 15 μg/ml proteinase K for 15 min at
room temperature and then washed with PBS. Endogen-
ous peroxidase was inactivated by 3% H2O2 for 5 min at
room temperature and then washed with PBS. Sections
were immersed in terminal deoxynucleotidyltransferase
(TdT) buffer containing deoxynucleotidyl transferase
and biotinylated dUTP in TdT buffer, incubated in a
humid atmosphere at 37°C for 90 min, and then washed
with PBS. The sections were incubated at room tem-
perature for 30 min with anti-horseradish peroxidase-
conjugated antibody, and the signals were visualized
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cells/high-power field was counted in 5 to 10 fields for
each coded slide.
2.11 Statistical evaluation
All values in the figures and text are expressed as mean ±
standard error of the mean (SEM) of N observations. For
the in vivo studies n represents the number of animals
studied. In the experiments involving histology or immu-
nohistochemistry, the figures shown are representative of
at least three experiments (histological or immunohisto-
chemistry coloration) performed on different experimen-
tal days on the tissue sections collected from all the
animals in each group. In the experiments involving
histology or immunohistochemistry, the figures shown
are representative of at least three experiments per-
formed on different experimental days. The results were
analyzed by one-way ANOVA followed by a Bonferroni
post-hoc test for multiple comparisons. A p value of less
than 0.05 was considered significant. BMS scale data
were analyzed by the Mann-Whitney test and considered
significant when p was <0.05.
3. Results
3.1 MK801 treatment reduces the severity of spinal cord
trauma
The severity of the trauma at the level of the perile-
sional area, assessed by the presence of edema as well as
alteration of the white matter and infiltration of leuko-
cytes, was evaluated 24 h after injury by hematoxylin/
eosin (H&E) staining. The severity of trauma in the peri-
lesional area, assessed by presence of edema and white
matter alteration (Figure 1b and see histological score
g), was evaluated 24 h after injury. Important damage
was observed in spinal cord tissue from SCI mice, when
compared to sham-operated mice (Figure 1a). Notably,
protection against injury was observed in SCI-operated
mice that have been treated with MK801at the dose of
2 mg/kg administered i.p. 30 min and 6 hours after
trauma (Figure 1c see histological score g). Moreover, to
evaluate the severity of the trauma we also observed the
alteration in the reticular and nervous fibers tissues
structure by silver impregnation. A normal presence of
reticular and nervous fibers was observed in the spinal
cord section from sham-operated mice (Figure 1d). On
the contrary, an alteration of reticular and nervous fibers
was detected in the spinal cord tissues collected at
24 hours after SCI (Figure 1e). Treatment with
MK801at the dose of 2 mg/kg administered i.p. 30 min
and 6 hours after trauma reduced the alteration of reti-
cular and nervous fibers associated with SCI (Figure 1f).
In order to evaluate if histological damage to the spinal
cord was associated with a loss of motor function, the
BMS locomotors rating scale score was evaluated. While
motor function was only slightly impaired in sham mice
(data not shown), mice subjected to SCI had significant
deficits in movement (Figure 1h). MK801 treatment at
the dose of 2 mg/kg administered i.p. 30 min and 6
hours after trauma significantly ameliorated the func-
tional deficits induced by SCI (Figure 1h).
3.2 Effect of MK801 on IB-a degradation,
phosphorylation of p65 on Ser536, NF-B p65
Most inflammatory mediators, including iNOS, IL-1b
and TNF-a a r ec o n t r o l l e db yN F - B, a transcription fac-
tor important in inflammatory process, which is kept
inactive by IB [29] in the cytosol. By western blot analy-
sis, we evaluated IB-a degradation, the phosphorylation
of Ser536 on the NF-B subunit p65 and nuclear NF-B
p65 to investigate the cellular mechanisms by which
treatment with MK801 may attenuate the development
of SCI. A basal level of IB-a was detected in the spinal
cord homogenates from sham-operated animals, whereas
SCI mice showed reduced IB-a level (Figure 2a, a1).
MK801 treatment at the dose of 2 mg/kg administered
i.p. 30 min and 6 hours after trauma reduced the SCI-
induced IB-degradation (Figure 2a, a1). Moreover, SCI
caused a significant increase in the phosphorylation of
NF-B p65 on Ser536 at 24 h after the injury; instead the
treatment with MK801 at the dose of 2 mg/kg adminis-
tered i.p. 30 min and 6 hours after trauma reduced signif-
icantly the phosphorylation of NF-B p65 on Ser536
(Figure 2 b, b1). In addition, the levels of the NF-Bp 6 5
in the nuclear extracts from the spinal cord tissue were
also significantly increased at 24 h after SCI compared
with the sham-operated mice. MK801 treatment at the
dose of 2 mg/kg administered i.p. 30 min and 6 hours
after trauma significantly reduced the levels of nuclear
NF-B p65 protein as shown in Figure 2c and 2c1.
3.3 MK801 modulates cytokines expression and
neutrophil infiltration after SCI
To test whether MK801 modulates the inflammatory
process through the regulation of secretion of pro-
inflammatory cytokines, we analyzed spinal cord tissue
levels of TNF-a and IL-1b. A substantial increase in
TNF-a and IL-1b production was found in spinal cord
tissues samples collected from SCI mice 24 h after SCI
(Figure 3a and 3b, respectively). Spinal cord levels of
TNF-a and IL-1b were significantly attenuated in SCI-
operated mice that have been treated with MK801 at the
dose of 2 mg/kg administered i.p. 30 min and 6 hours
after trauma (Figure 3a and 3b, respectively). Similarly, at
24 h after SCI, expression of TNF-a and IL-1b in the
spinal cord tissues were determined by the immunohisto-
logical staining (Figure 4). Spinal cord sections obtained
Esposito et al. BMC Neuroscience 2011, 12:31
http://www.biomedcentral.com/1471-2202/12/31
Page 5 of 21from sham-operated mice did no stain either for TNF-a
and IL-μ (Figure 4a and 4d respectively, see densitometry
analysis g). A substantial increase in TNF-a (Figure 4b,
see densitometry analysis g) and IL-1b (Figure 4e, see
densitometry analysis g) expression was observed in
spinal cord section obtained at 24 h after SCI, while
MK801 treatment at the dose of 2 mg/kg administered i.
p. 30 min and 6 hours after trauma significantly reduced
the degree of positive staining for these pro-inflammatory
cytokines (Figure 4c and 4f respectively, see densitometry
analysis g). The histological pattern of spinal cord injury
seemed to be correlated with the influx of leukocytes into
the spinal cord. Therefore, we investigated the effect of
the treatment of MK801 on the infiltration of neutrophils
by measuring myeloperoxidase (MPO) that is a lysosomal
protein stored in azurophilic granules of the neutrophil
(Figure 3c). MPO activity was significantly elevated in the
spinal cord at 24 h after injury in mice subjected to SCI
when compared with sham-operated mice. The treatment
with MK801 at the dose of 2 mg/kg administered i.p.
Figure 1 Effect of MK801 treatment on histological alterations and on hind limb motor disturbance of the spinal cord tissue 24 h
after injury. Spinal cord samples were collected from perilesional area and were stained with H&E and silver impregnation. The number of
analyzed samples represents the number of animals studied (N = 10). (a): no histological alteration was observed in tissue sections obtained
from sham-operated mice stained with H&E. (b): a significant damage to the spinal cord was assessed in SCI-operated mice stained with H&E. (c):
a strong protection from SCI was observed in the tissue collected from mice treated with MK801 at the dose of 2 mg/kg administered i.p. 30
min and 6 hours after trauma stained with H&E. In sham-operated mice a normal presence of reticular and nervous fibers was observed by silver
impregnation (d). On the contrary, in the spinal cord tissues collected at 24 hours after SCI an important alteration of reticular and nervous fibers
was observed (e). MK801 treatment at the dose of 2 mg/kg administered i.p. 30 min and 6 hours after trauma appreciably reduced the alteration
of reticular and nervous fibers associated with SCI (f). The histological score (g) was evaluated by an independent observer. The degree of motor
disturbance was assessed every day until 10 days after SCI by Basso mouse scale (BMS) open-field score. Treatment with MK801 at the dose of
2 mg/kg administered i.p. 30 min and 6 hours after trauma reduces the motor disturbance after SCI (h). This figure is representative of at least 3
experiments performed on different experimental days. ND: not detectable. Values shown are mean ± s.e. of 10 mice for each group; *p < 0.01
vs Sham; °p < 0.01 vs SCI
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neutrophils infiltration in the spinal cord tissues at 24 h
after the trauma (Figure 3c).
3.4 MK801 modulates the expression of nitrotyrosine,
iNOS, and nNOS after SCI
To determine the role of nitric oxide (NO) produced dur-
ing SCI, twenty-four hours after trauma iNOS expression,
and nitrotyrosine, a specific marker of nitrosative stress,
were determined by immunohistochemical analysis in
the spinal cord sections. Spinal cord sections from sham-
operated mice did not stain either for iNOS, and nitrotyro-
sine (Figure 5a and 5d, respectively), whereas spinal cord
sections obtained from SCI-operated mice exhibited posi-
tive staining for iNOS (Figure 5b, see densitometry
analysis g), and nitrotyrosine (Figure 5e, see densitometry
analysis g). The positive staining was mainly localized in
various inflammatory cells in the white matter. MK801
treatment at the dose of 2 mg/kg administered i.p. 30 min
and 6 hours after trauma was able to reduce the degree of
positive staining for iNOS (Figure 5c, densitometry analy-
sis g), and nitrotyrosine (Figure 5f, densitometry analysis
g) in the spinal cord at 24 h after trauma. To better char-
acterize the degree of spinal cord injury, we also evaluated
by western blot analysis the level of neuronal nitric oxide
synthase (nNOS) protein. In spinal cord sections obtained
at 24 hours, we observed basal levels of nNOS in Sham
group (Figure 5h, h1); a significant increase in the level of
nNOS protein was found twenty-four hours after spinal
cord compression. The treatment with MK801 at the
Figure 2 Effects of MK801 treatment on NF-B and nuclear NF-B p65. By western blot analysis, a basal level of IB-a was detected in the
spinal cord from sham-operated animals (a, a1), whereas IB-a levels were substantially reduced in SCI mice (a, a1). MK801 treatment (2 mg/kg
30 min and 6 h after SCI induction) reduced the SCI-induced IB-a degradation (a, a1). In addition, SCI caused a significant increase in the
phosphorylation of Ser536 at 24 h (b, b1) and in nuclear NF-B p65 compared to the sham-operated mice (c, c1). MK801 treatment (2 mg/kg 30
min and 6 h after SCI induction) significantly reduced the phosphorylation of p65 on Ser536 (b, b1) and NF-B p65 levels as shown in panels c
and c1. a-tubulin and Laminin A/C were used as internal control. A representative blot of lysates obtained from each group is shown, and
densitometry analysis of all animals is reported. Respective densitometry analysis of protein bands from three separated experiments is reported
in a1, b1, and c1 (**p < 0.01 and ***p < 0.001 vs. Sham; #p < 0.05 and ###p < 0.001 vs. SCI).
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Page 7 of 21dose of 2 mg/kg administered i.p. 30 min and 6 hours
after trauma significantly influences nNOS levels
(Figure 5h, h1).
3.5 Effects of MK801 on COX-2 expression after SCI
Spinal cord sections from sham-operated mice did not
stain for COX-2 (Figure 6a, see densitometry analysis d),
whereas spinal cord sections obtained from SCI mice
exhibited positive staining for COX-2 (Figure 6b, see
densitometry analysis d) mainly localized in inflammatory
cells in the white and gray matter of the spinal cord
tissues. MK801 treatment at the dose of 2 mg/kg admi-
nistered i.p. 30 min and 6 hours after trauma reduced the
degree of positive staining for COX-2 (Figure 6c, see
densitometry analysis d) in the spinal cord.
Moreover, 24 h after SCI, the changes in expression
of COX-2 were also confirmed by western blot. COX-2
levels were appreciably increased in the spinal cord
from mice subjected to SCI (Figure 6e, e1). On the
contrary, MK801 treatment at the dose of 2 mg/kg
administered i.p. 30 min and 6 hours after trauma
reduced the SCI-induced COX-2 expression at basal
level (Figure 6e, e1).
3.6 MK801 reduces the expression of p-ERK1/2, and p-P38
after SCI
To investigate signaling cascades by which treatment
with MK801 may attenuate the development of spinal
cord injury, we also evaluated the activation of ERK1/2
and P38 by phosphorylation by western blot analysis.
Moreover, P38 MAPK has been implicated as a critical
mediator that positively regulates the expression of a
variety of genes involved in the acute phase response.
In spinal cord homogenates at 24 h after SCI a signifi-
cant increase in p-ERK1/2 levels were observed in SCI-
operated mice (Figure 7a, a1). Treatment of mice with
Figure 3 Effects of MK801 on TNF-a, IL-1b tissue levels and on MPO activity in spinal cord tissue. A substantial increase in TNF-a (a), and
IL-1b (b) was found in spinal cord tissues from SCI mice 24 h after SCI. MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction)
significantly attenuated TNF-a (a) and IL-1b (b) levels in the spinal cord. Following the injury, MPO activity in spinal cord from SCI mice was
significantly increased at 24 h after the damage in comparison to Sham groups (c). MK801 treatment (2 mg/kg 30 min and 6 h after SCI
induction) significantly attenuated neutrophils infiltration. Data are means ± s.e. means of 10 mice for each group. *p < 0.01 vs. Sham °p < 0.01
vs. SCI.
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Page 8 of 21Figure 4 Effects of MK801 on TNF-a and IL-1b expression in spinal cord tissue. Spinal cord sections were processed 24 h after SCI to
determine the immunohistological staining for TNF-a and IL-1b expression. No positive staining for TNF-a (a) and IL-1b (d) was found in the
spinal cord tissue from sham-operated mice. A substantial increase in TNF-a (b), and IL-1b (e) expression was found in spinal cord tissues from
SCI mice 24 h after SCI. MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction) significantly attenuated TNF-a (c) and IL-1b (f) levels in
the spinal cord. Densitometry analysis of immunohistochemistry photographs (n = 5 photos from each sample collected from all mice in each
experimental group) for TNF-a and IL-1b (g) from spinal cord tissues were assessed. Figure is representative of at least 3 experiments performed
on different experimental days. Data are expressed as % of total tissue area. Data are means ± s.e. of 10 mice for each group.*p < 0.05 vs. Sham.
°p < 0.01 vs. SCI. ND: not detectable.
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Page 9 of 21MK801 at the dose of 2 mg/kg administered i.p. 30 min
and 6 hours after trauma significantly reduced the level
of p-ERK1/2 (Figure 7a, a1). Moreover, pospho-P38
levels significantly increase after SCI (Figure 7b, b1).
MK801 treatment at the dose of 2 mg/kg administered
i.p. 30 min and 6 hours after trauma significantly
decreased the expression of p-P38 (Figure 7b, b1).
3.7 Effect of MK801 on Fas-ligand expression and
apoptosis in spinal cord after injury
Immunohistological staining for Fas ligand (FasL) in the
spinal cord was also determined 24 h after injury. Spinal
cord sections from sham-operated mice groups did not
stain for FasL (Figure 8a), whereas spinal cord sections
obtained from SCI mice exhibited positive staining for
this transmembrane protein in several inflammatory
cells of the gray and white matter (Figure 8b, see densi-
tometry analysis d). Treatment of mice with MK801 at
the dose of 2 mg/kg administered i.p. 30 min and
6 hours after trauma reduced the degree of positive
staining for FasL in the spinal cord sections (Figure 8c,
see densitometry analysis d). Moreover, to test whether
spinal cord damage was associated to cell death by
apoptosis, we measured TUNEL-like staining in the
perilesional spinal cord tissue. Almost no apoptotic cells
were detected in the spinal cord from sham-operated
mice (Figure 8e and 8h). At 24 h after the trauma, tis-
sues from SCI mice demonstrated a marked appearance
Figure 5 Effects of MK801 on nitrotyrosine formation, iNOS and nNOS expression. iNOS expression was evaluated by immunoistochemical
analysis in the spinal cord section 24 h after SCI. Spinal cord section from sham-operated mice did not stain for iNOS (a), whereas spinal cord
section obtained from SCI-operated mice exhibited positive staining for iNOS (b) mainly localized in various inflammatory cells in the gray
matter. MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction) reduced the degree for positive staining for iNOS in the spinal cord
tissue (c). Moreover the tissue sections obtained from SCI mice group demonstrate a positive staining also for nitrotyrosine mainly localized in
inflammatory, in nuclei of Schwann cells in the white and gray matter (e). MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction)
reduced the degree of positive staining for nitrotyrosine (f). On the contrary spinal cord obtained from Sham-operated mice did not staining for
nitrotyrosine (d). Densitometry analysis of immunocytochemistry photographs (n = 5 photos from each sample collected from all mice in each
experimental group) for iNOS and nitrotyrosine (g) from spinal cord tissues was assessed. The assay was carried out by using Optilab Graftek
software on a Macintosh personal computer (CPU G3-266). Data are expressed as % of total tissue area. Moreover spinal cord sections were
processed at 24 h after SCI to determine also the nNOS levels by western blot analysis; nNOS expression was significantly increased in the spinal
cord from SCI mice (h and h1). On the contrary, MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction) significantly restores the
expression of nNOS (h and h1). The relative expression of the protein band was standardized for densitometry analysis to a-tubulin levels and
reported in panel h1, and expressed as mean ± s.e.m. from n = 5/6 spinal cord for each group. This figure is representative of at least 3
experiments performed on different experimental days. *p < 0.01 vs Sham; °p < 0.01 vs SCI.
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Page 10 of 21of dark brown apoptotic cells and intercellular apoptotic
fragments (Figure 8f and 8h). In contrast, tissues
obtained from mice treated with MK801 treatment at
the dose of 2 mg/kg administered i.p. 30 min and 6
hours after trauma demonstrated no apoptotic cells or
fragments (Figure 8g and 8h).
3.8 MK801 reduces CD30 and CD30 ligand expression
No positive staining either for CD30 or for CD30L in
spinal cord collected from sham-treated mice (Figure 9a
and 9d, respectively). The spinal cord sections from
mice subject to SCI stained positively for CD30 and
CD30L (Figure 9b and 9e, respectively see densitometry
analysis g) mainly localized in infiltrating lymphocytes.
In contrast, there was no staining for CD30 as well as
for CD30L in spinal cord tissue from SCI-operated mice
receiving MK801 at the dose of 2 mg/kg administered i.
p. 30 min and 6 hours after trauma (Figure 9c and 9f,
respectively see densitometry analysis g).
3.9 MK801 treatment reduce the T-cell infiltration
Since the anti-inflammatory effect of MK801 may also be
due to inhibition of leukocyte extravasation, we analyzed
leukocyte infiltration by immunohistochemical staining for
CD4
+ (Figure 10) and CD8
+ a (Figure 11) and CD8
+ b
(Figure 12) T lymphocytes at the injury site. There was no
staining for CD4
+(Figure 10a, see densitometry analysis d),
CD8
+ a (Figure 11a, see densitometry analysis d) and CD8
Figure 6 Effects of MK801 on COX-2 expression. COX-2 expression was evaluated by immunoistochemical analysis in the spinal cord section
24 h after SCI. Spinal cord section from sham-operated mice did not stain for COX-2 (a), whereas spinal cord section obtained from SCI-
operated mice exhibited positive staining for COX-2 (b) mainly localized in various inflammatory cells of white and gray matter of spinal cord.
MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction) reduced the degree for positive staining for COX-2 in the spinal cord tissue (c).
Densitometry analysis of immunocytochemistry photographs (n = 5 photos from each sample collected from all mice in each experimental
group) for COX-2 (d) from spinal cord tissues was assessed. The assay was carried out by using Optilab Graftek software on a Macintosh personal
computer (CPU G3-266). Data are expressed as % of total tissue area. This figure is representative of at least 3 experiments performed on
different experimental days. *p < 0.01 vs. Sham; °p < 0.01 vs. SCI. Moreover spinal cord sections were processed at 24 h after SCI to determine
also the COX-2 levels by western blot analysis. COX-2 was significantly increased in the spinal cord from SCI mice (e and e1). On the contrary,
MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction) significantly reduced the expression of COX-2 induced by SCI (e and e1). The
relative expression of the protein band was standardized for densitometry analysis to a-tubulin levels and reported in h1, and expressed as
mean ± s.e.m. from n = 5/6 spinal cord for each group. **p < 0.01 vs. Sham;
###p < 0.001 vs. SCI.
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Page 11 of 21+ b T lymphocytes (Figure 12a see densitometry analysis d)
in spinal cord obtained from sham-operated mice.
Whereas a substantial increase for CD4
+ (Figure 10b, see
densitometry analysis d), CD8
+ a (Figure 11b, see densito-
metry analysis d) and CD8
+ b cells (Figure 12b, see densi-
tometry analysis d) were observed in the spinal cord tissue
collected from SCI mice. MK801 treatment at the dose of
2 mg/kg administered i.p. 30 min and 6 hours after trauma
significantly lowered the degree of positive staining for
CD4
+ (Figure 10c, see densitometry analysis d), CD8
+ a
(Figure 11c, see densitometry analysis d) and CD8
+ b
(Figure 12c and 12D) T lymphocytes.
3.10 Effects of MK801 on neurotrophic factors
By western blot analysis we evaluated the levels of two
important neurotrophic factors that are release by
microglia and macrophages in the CNS, glial cell line-
derived neurotrophic factor (GDNF) and brain-derived
neurotrophic factor (BDNF). We observed a basal levels
of BDNF and GDNF in the spinal cord section obtained
from Sham-operated animals (Figure 13a, a1 and 1b,
b1). On the contrary, at 24 hours after SCI a loss of
both neurotrophic proteins was observed in the perile-
s i o n e dz o n e( F i g u r e1 3 a ,a 1a n d1 b ,b 1 ) .T h et r e a t m e n t
with MK801 at the dose of 2 mg/kg administered i.p.
30 min and 6 hours after trauma significantly restored
the levels of BDNF up to that of uninjured mice. More-
over, for GDNF expression it was evident a trend of
increase after MK801 treatment at the dose of 2 mg/kg
administered i.p. 30 min and 6 hours after trauma
(Figure 13a, a1 and 1b, b1).
4. Discussion
Glutamate is released in the white matter in a range of
pathological conditions, in particular in the SCI, and has
been thought to damage oligodendrocytes [4].
SCI induces lifetime disability, and no suitable ther-
apy is available to treat victims or to minimize their
suffering [30].
In the acutely injured of spinal cord, an inflammatory
response develops within hours after injury and is char-
acterized by the infiltration of neutrophils, the activation
of microglia and causes the death of a number of neu-
rons [31].
Traumatic events, as SCI or neuronal diseases, cause
an excessive accumulation of glutamate outside cells
and lead to an increase flux of calcium ions into the
cells, via NMDA receptor channel, with subsequent neu-
ronal damage characterized by changes of dendrite
structures and destruction of myelin.
Figure 7 Effect of MK801 on activated kinases. The spinal cord extract were immunoblotted for the -phosphorylated form of ERK. pERK1/2 is
up-regulated in injured mice compared with Sham-operated mice (a and a1). Spinal cord levels of pERK1/2 were significantly attenuated in
MK801 (2 mg/kg 30 min and 6 h after SCI induction)-treated mice compared with SCI animals (a and a1). Moreover, SCI caused also a significant
increase in phospho-p38 expression at 24 h after trauma (b and b1). The MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction)
significantly reduced p38 expression (b and b1). The relative expression of the protein band was standardized for densitometry analysis to
a-tubulin levels and reported in a1, and b1. *p < 0.05 and **p < 0.01 vs. Sham; #p < 0.05 and ##p < 0.01 vs SCI.
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Page 12 of 21Figure 8 MK801 treatment reduced Fas-ligand expression and TUNEL-like staining in the perilesional spinal cord tissue. No positive
staining for Fas-ligand was found in the spinal cord tissue collected from Sham-operated mice (a). A substantial increase in Fas-ligand
expression was found in inflammatory cells, in white matter and gray matter of the spinal cord tissues collected at 24 h after SCI (b). Spinal cord
levels of Fas-ligand were significantly attenuated by MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction) (c). Densitometry analysis of
immunocytochemistry photographs (n = 5 photos from each sample collected from all mice in each experimental group) for Fas-ligand (d) was
performed. In sham animals, no apoptotic cells were observed (e). At 24 h after the trauma, SCI mice demonstrated a marked appearance of
dark brown apoptotic cells and intercellular apoptotic fragments (f). In contrast, tissues obtained from mice treated with MK801 (2 mg/kg 30 min
and 6 h after SCI induction) demonstrated no apoptotic cells or fragments (g). The number of TUNEL positive cells/high-power field was
counted in 5 to 10 fields for each coded slide (h). Figure is representative of at least 3 experiments performed on different experimental days.
*p < 0.01 vs Sham; °p < 0.01 vs SCI. ND: not detectable
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Page 13 of 21Figure 9 MK801 treatment reduced CD30 and CD30-ligand expression. Spinal cord sections were processed 24 h after SCI to determine the
immunohistological staining for CD30 and CD30-ligand expression. No positive staining for CD30 (a) and CD30-L (d) was found in the spinal
cord tissue from sham-operated mice. A substantial increase in CD30 (b) and CD30-L (e) expression was found in spinal cord tissues from SCI
mice 24 h after SCI. MK801 treatment (2 mg/kg 30 min and 6 h after SCI induction) significantly attenuated CD30 (c) and CD30-L (f) levels in the
spinal cord. Densitometry analysis of immunohistochemistry photographs (n = 5 photos from each sample collected from all mice in each
experimental group) for CD30 and CD30-L (g) from spinal cord tissues were assessed. Figure is representative of at least 3 experiments
performed on different experimental days. Data are expressed as % of total tissue area. Data are means ± s.e. of 10 mice for each group.*p <
0.05 vs. Sham. °p < 0.01 vs. SCI. ND: not detectable.
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Page 14 of 21Figure 10 Effect of MK801 treatment on T-cell infiltration. By immunohistochemical analysis we analyzed leukocyte infiltration. There was no
staining for CD4
+ in spinal cord obtained from Sham mice (a). Instead positive staining for CD4
+ cells was observed in the spinal cord tissue
collected from SCI-mice (b), on the contrary CD4
+ lymphocytes infiltrates were significantly attenuated in MK801(2 mg/kg 30 min and 6 h after
SCI induction)-treated mice (c). Densitometry analysis of immunohistochemistry photographs (n = 5 photos from each sample collected from all
mice in each experimental group) for CD4
+ (d) from spinal cord tissues were assessed. Figure is representative of at least 3 experiments
performed on different experimental days. Data are expressed as % of total tissue area. Data are means ± s.e. of 10 mice for each group.
*p < 0.05 vs. Sham. °p < 0.01 vs. SCI. ND: not detectable.
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Page 15 of 21Figure 11 Effect of MK801 treatment on CD8 alpha T-cell infiltration. By immunohistochemical analysis we also analyzed levels of CD8
+
alpha infiltration. There was no staining for CD8
+ alpha T lymphocytes in spinal cord obtained from sham-operated mice (a). Instead CD8
+alpha
and beta cells were observed in the spinal cord tissue collected from SCI-mice (b see particle b1), on the contrary, CD8
+ alpha T lymphocytes
infiltrates were significantly attenuated in MK801(2 mg/kg 30 min and 6 h after SCI induction)-treated mice (c). Densitometry analysis of
immunohistochemistry photographs (n = 5 photos from each sample collected from all mice in each experimental group) for CD8
+ alpha (d)
from spinal cord tissues were assessed. Figure is representative of at least 3 experiments performed on different experimental days. Data are
expressed as % of total tissue area. Data are means ± s.e. of 10 mice for each group.*p < 0.05 vs. Sham. °p < 0.01 vs. SCI. ND: not detectable.
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Page 16 of 21Figure 12 Effect of MK801 treatment on CD8 beta T-cell infiltration. By immunohistochemical analysis we also analyzed levels of CD8
+ beta
T-cell infiltration. There was no staining for CD8
+ beta T lymphocytes in spinal cord obtained from sham-operated mice (a). Instead CD8
+ beta
cells were observed in the spinal cord tissue collected from SCI-mice (b), on the contrary, CD8
+ beta T lymphocytes infiltrates were significantly
attenuated in MK801 MK801(2 mg/kg 30 min and 6 h after SCI induction)-treated mice (c). Densitometry analysis of immunohistochemistry
photographs (n = 5 photos from each sample collected from all mice in each experimental group) for CD8
+ beta (d) from spinal cord tissues
were assessed. Figure is representative of at least 3 experiments performed on different experimental days. Data are expressed as % of total
tissue area. Data are means ± s.e. of 10 mice for each group.*p < 0.05 vs. Sham. °p < 0.01 vs. SCI. ND: not detectable.
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Page 17 of 21Figure 13 Effect of MK801 on neurotrophin expression. Spinal cord sections were processed at 24 h after SCI to determine the levels for
BDNF and GDNF by western blot analysis. A basal level of BDNF and GDNF were detected in the spinal cord from Sham-operated animals,
whereas BDNF and GDNF levels were substantially reduced in SCI mice (a, a1 and b, b1). MK801 MK801 (2 mg/kg 30 min and 6 h after SCI
induction) treatment significantly blunted SCI-induced reduction of BDNF, while showed a trend of increase for GDNF (a, a1 and b, b1). The
relative expression of the protein band was standardized for densitometry analysis to a-tubulin levels and reported in h1, and expressed as
mean ± s.e.m. from n = 5/6 spinal cord for each group. *p < 0.05 vs Sham; ##p < 0.01 vs SCI.
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Page 18 of 21The finding that an excessive accumulation of gluta-
mate was generated following injury suggests that treat-
ment with MK801 could attenuate the pathogenesis of
SCI. We confirm here that MK801 exerts beneficial
effects on the development of spinal cord damage and
ameliorates the motor disturbance, as reported by other
research groups [16,32].
Accumulation and activation of inflammatory cells are
initial events of tissue injury and are regulated at the
transcriptional level. NF-B plays a central role in the
regulation of many genes responsible for the generation
of mediators or proteins involved in secondary damage
[33]. The balance between proinflammatory and prosur-
vival roles of NF-B may depend on the phosphoryla-
tion status of p65, and excessive release of glutamate
play a central role in this process. In this study on acute
SCI we documented increased production of inflamma-
tory mediators after SCI. Also changes in COX-2
expression were evident as previously indicated [34].
MK801 treatment reduced COX-2 expression contribut-
ing to the attenuation of inflammation associated to this
model of SCI.
Generation of reactive oxygen species (ROS) also
appears to play a critical role in the induction of neuro-
logical dysfunctions in the course of SCI. It has been
known that NO is the initiator of tissue oxidative stress
and promoter of the pro-inflammatory reactions in SCI
[35]. Activation of the NMDA receptor generates NO
[36], and over-expression of nNOS leads to the exces-
sive production of NO, which is the link between the
excitatory amino acids and subsequent cell damage [37].
In this study western blot results have shown that SCI-
induced nNOS expression was attenuated by MK801.
Thus, the neuroprotective mechanism of MK801
involved regulating nNOS expression.
Glutamate triggers the production of NO and super-
oxide, which can lead to the formation of peroxynitrite
(ONOO
-). Furthermore, nitrotyrosine formation was
initially proposed as a relatively specific marker for the
detection of the endogenous formation of ONOO
-[38]
that contributes to secondary neuronal damage [39].
We showed that the use of the NMDA receptor antago-
nists MK801 reduced glutamate-mediated ONOO
-
generation.
Our results indicate that the glutamate released after
SCI activates ERK1/2 and p38 in the mouse spinal cord
via NMDA receptors. But the incomplete blocking of
p38 phosphorylation by 2 mg/kg MK801 indicates that
MAPKs, especially p38, are also activated by NMDA
receptor independent mechanisms.
The extrinsic Fas pathway is sufficient to induce com-
plete apoptosis in certain cell types as well as oligoden-
drocytes, astrocytes, and microglia through caspase-8
activation [40]. In this study, we demonstrated the first
evidence that treatment with MK801 significantly
reduced the FasL positive staining.
Moreover in the pathways of apoptosis, CD30 initiates
a negative growth signal leading to apoptosis. In this
s t u d yw ed e m o n s t r a t e dt h a tM K 8 0 1i sc l e a r l ya b l et o
blockade CD30-CD30L interaction, reducing inflamma-
tory and apoptotic response.
Moreover, it has been demonstrates the presence of
specific high affinity glutamate binding site on the sur-
face of human lymphocytes, CD4
+ ,C D 8
+ alpha and
CD8 beta T cells. The presence of NMDA receptors on
the surface of this type of cells is linked with T cell
function and is essential for T cell proliferation [41].
MK801 exert its anti-inflammatory effects inhibiting leu-
kocytes extravasation at the injury site.
Moreover, we also investigated the capacity of MK801
to enhance functional outcome and to reduce the spinal
cord lesions associated to SCI restoring neurotrophic
factors. We focused our attention on the role of two
specific neurotrophins, as BDNF and GDNF that were
markedly decreased following induction of SCI. The
treatment with MK801 restored BDNF expression at
basal levels and increased GDNF levels, showing that
MK801 was able to promoting the initiation of neuro-
trophic substance after SCI.
5. Conclusions
Unfortunately, all clinical tests of glutamate antagonists
for neuroprotection have failed. The reasons for the fail-
ure of the NMDA antagonists for example in stroke and
traumatic brain injury trials have been extensively dis-
cussed [42,43]. In some cases, failure is attributable to
class-specific factors.
However, a factor not easily addressed is the time
between onset of injury and initiation of drug treatment.
It is important that NMDA receptors are blocked during
the period when glutamate is released pathologically,
such as during ischemia occurring secondary to spinal
cord injury.
The preclinical literature indicates that efficacy with
NMDA receptor antagonists can be realized with treat-
ment initiated up to 2 h after injury [44], although the
optimal timing may be shorter [45].
Nevertheless, NMDA receptor antagonists remain an
attractive target for treatment of acute injury, and clini-
cal trials such as the FAST-MAG trial have demon-
strated the feasibility of initiating treatment within 2 h
of the onset of injury [46,47], which should consent to a
more rigorous evaluation of the neuroprotective poten-
tial of NMDA receptor antagonists.
However, since the pathophysiology of spinal cord
lesion is multifactorial and multiphase, effective treat-
ments are likely to require the application of combined
strategies [48].
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Page 19 of 21In conclusion, the current study provides evidence
that MK801 was able to reduce all parameters involving
in inflammation, axonal destruction and demyelization
at the site of impact in spinal cord trauma. Moreover,
this study confirms the well documented neuroprotec-
tive effects of this drug and lend support to the poten-
tial importance of NMDA antagonists as therapeutic
agents in the treatment of acute SCI.
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